Incidence of Plasmodium falciparum malaria infection in 6-month to 45-year-olds on selected areas of Bioko Island, Equatorial Guinea

Abstract Background Extensive malaria control measures have been implemented on Bioko Island, Equatorial Guinea over the past 16 years, reducing parasite prevalence and malaria-related morbidity and mortality, but without achieving elimination. Malaria vaccines offer hope for reducing the burden to...

Full description

Saved in:
Bibliographic Details
Published inMalaria journal Vol. 20; no. 1; pp. 1 - 322
Main Authors Nchama, Vicente Urbano Nsue Ndong, Said, Ali Hamad, Mtoro, Ali, Bidjimi, Gertrudis Owono, Owono, Marta Alene, Maye, Escolastica Raquel Mansogo, Mangue, Martin Eka Ondo, Okomo, Genaro Nsue Nguema, Pasialo, Beltran Ekua Ntutumu, Ondo, Dolores Mbang, Lopez, Maria-Silvia Angue, Mochomuemue, Fortunata Lobede, Obono, Mariano Obiang, Besaha, Juan Carlos Momo, Chuquiyauri, Raul, Jongo, Said Abdallah, Kamaka, Kassim, Kibondo, Ummi Abdul, Athuman, Thabit, Falla, Carlos Cortez, Eyono, Jeremías Nzamio Mba, Smith, Jordan Michael, García, Guillermo A., Raso, José, Nyakarungu, Elizabeth, Mpina, Maxmillian, Schindler, Tobias, Daubenberger, Claudia, Lemiale, Laurence, Billingsley, Peter F., Sim, B. Kim Lee, Richie, Thomas L., Church, L. W. Preston, Olotu, Ally, Tanner, Marcel, Hoffman, Stephen L., Abdulla, Salim
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 20.07.2021
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Background Extensive malaria control measures have been implemented on Bioko Island, Equatorial Guinea over the past 16 years, reducing parasite prevalence and malaria-related morbidity and mortality, but without achieving elimination. Malaria vaccines offer hope for reducing the burden to zero. Three phase 1/2 studies have been conducted successfully on Bioko Island to evaluate the safety and efficacy of whole Plasmodium falciparum (Pf) sporozoite (SPZ) malaria vaccines. A large, pivotal trial of the safety and efficacy of the radiation-attenuated Sanaria ® PfSPZ Vaccine against P. falciparum is planned for 2022. This study assessed the incidence of malaria at the phase 3 study site and characterized the influence of socio-demographic factors on the burden of malaria to guide trial design. Methods A cohort of 240 randomly selected individuals aged 6 months to 45 years from selected areas of North Bioko Province, Bioko Island, was followed for 24 weeks after clearance of parasitaemia. Assessment of clinical presentation consistent with malaria and thick blood smears were performed every 2 weeks. Incidence of first and multiple malaria infections per person-time of follow-up was estimated, compared between age groups, and examined for associated socio-demographic risk factors. Results There were 58 malaria infection episodes observed during the follow up period, including 47 first and 11 repeat infections. The incidence of malaria was 0.25 [95% CI (0.19, 0.32)] and of first malaria was 0.23 [95% CI (0.17, 0.30)] per person per 24 weeks (0.22 in 6–59-month-olds, 0.26 in 5–17-year-olds, 0.20 in 18–45-year-olds). Incidence of first malaria with symptoms was 0.13 [95% CI (0.09, 0.19)] per person per 24 weeks (0.16 in 6–59-month-olds, 0.10 in 5–17-year-olds, 0.11 in 18–45-year-olds). Multivariate assessment showed that study area, gender, malaria positivity at screening, and household socioeconomic status independently predicted the observed incidence of malaria. Conclusion Despite intensive malaria control efforts on Bioko Island, local transmission remains and is spread evenly throughout age groups. These incidence rates indicate moderate malaria transmission which may be sufficient to support future larger trials of PfSPZ Vaccine. The long-term goal is to conduct mass vaccination programmes to halt transmission and eliminate P. falciparum malaria.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1475-2875
1475-2875
DOI:10.1186/s12936-021-03850-8